First European Primary Care MASLD/MASH Summit - Scroll down

---

Overall Learning Objectives:

1. Recognize and diagnose fatty liver disease, including MASLD and MASH, in at-risk patient populations through appropriate screening and assessment tools.

2. Select and interpret appropriate diagnostic investigations to evaluate suspected cases of fatty liver disease.

3. Implement evidence-based treatment strategies for patients with hepatic steatosis, tailoring interventions to individual risk profiles and disease severity.

4. Identify and refer patients with advanced or high-risk fatty liver disease to specialized care for further management.

MODERATOR: JEFFREY LAZARUS

Thursday, December 4, 2025. 

6:00 p.m. - 6:05 p.m.

Welcome & Opening Remarks Michael Betel, Fatty Liver Alliance
Marko Korenjak, European Liver Patients’ Association
Juan Manuel Mendive, European Society For Primary Care Gastroenterology (ESPCG) 

6:05 p.m. - 6:30 p.m.

Understanding MASLD and MASH and the relationship between Primary Care and the Hepatologist

• Define MASLD and MASH using current, practical terminology.
• Identify key screening criteria and risk factors for fatty liver disease in primary care.
• Summarize updated guidelines and nomenclature relevant to MASLD and MASH.

Jörn Schattenberg, University Medical Center Homburg 

6:30 p.m. - 7:00 p.m.

Primary Care Toolbox: Managing Fatty Liver in Daily Practice

• Select appropriate laboratory and non-invasive tests for the assessment of fatty liver disease.
• What labs to order
• Demonstrate how to integrate liver health assessments into routine patient visits.
• Interpret results from NITs (FIB-4, Transient Elastography, ultrasound, ELF, and non-invasive scores) and determine when to use each tool.
• Apply workflow strategies to optimize efficiency and improve patient care in primary care settings.

Louise Campbell, Tawazun Health
Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGLOBAL)

7:00 p.m. - 7:25 p.m.

The Patient Voice: MASLD/MASH Real-World Experience

• Describe common barriers patients face in accessing care for MASLD/MASH (e.g., stigma, confusion, fear).
• Discuss patient experiences and factors that contributed to successful management.
• Assess the impact of primary care interventions on patient outcomes.

José Willemse, Liver Patients International
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow

7:25 p.m. - 7:55 p.m.

Lifestyle Rx: Pearls for a busy Primary Care Practice

• Addressing real world nutritional advice – Practical strategies for Primary Care
• Addressing real world exercise advice - Practical strategies for Primary Care
• Recommend practical nutritional and lifestyle strategies for patients with fatty liver disease.
• Address patient challenges and stigma related to lifestyle modification.
• Demonstrate brief, effective lifestyle interventions suitable for busy clinical settings

Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Jonathan Stine, Penn State Health Milton S. Hershey Medical Center

7:55 p.m. - 8:25 p.m.

Integrating Available Treatment Approaches in Primary Care for management of Fatty Liver disease

• Review the role of GLP-1s, statins, insulin sensitizers, and emerging therapies in MASLD/MASH management.
• Evaluate medication choices considering comorbidities such as T2D, obesity, CKLM and bariatric surgery
• Summarize current and upcoming guidelines for pharmacologic management.

Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN

8:25 p.m. - 8:55 p.m.

Case-Based Panel: What Would You Do?

• Analyze real-world cases to identify appropriate diagnostic and management strategies for diabetes and obesity
• Evaluate patient with advanced fibrosis on Transient Elastography but no symptoms
• Evaluate Young patient with obesity and normal liver enzymes
• Differentiate between patients who require specialist referral and those manageable in primary care.
• Formulate individualized care plans based on case scenarios.

James KIM, University of Calgary
Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN
Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow

8:55 p.m. - 9:00 p.m.

Closing Remarks: Primary Care as Liver Health Leaders Michael Betel, Fatty Liver Alliance